Diovan advisory committee
Executive Summary
Novartis' Diovan (valsartan) will be reviewed by FDA's Cardiovascular & Renal Drugs Advisory Committee Oct. 11 for the treatment of heart failure. The priority sNDA was submitted April 27. The meeting will be held at the National Institutes of Health Masur Auditorium in Bethesda, Md. beginning at 9 a.m